LT3124610T - Hbv gydymas - Google Patents

Hbv gydymas

Info

Publication number
LT3124610T
LT3124610T LTEP16188642.9T LT16188642T LT3124610T LT 3124610 T LT3124610 T LT 3124610T LT 16188642 T LT16188642 T LT 16188642T LT 3124610 T LT3124610 T LT 3124610T
Authority
LT
Lithuania
Prior art keywords
hbv treatment
hbv
treatment
Prior art date
Application number
LTEP16188642.9T
Other languages
English (en)
Inventor
Michael Wayne Graham
Peter French
York Yuan Yuan Zhu
Yixiang Lu
Tiejun Li
Yuncheng Sun
Xiaojun Tang
Li SHAN
Original Assignee
Benitec Biopharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201010522003.3A external-priority patent/CN101979557B/zh
Priority claimed from CN201010522005.2A external-priority patent/CN101979558B/zh
Priority claimed from CN201010521975.0A external-priority patent/CN101979555B/zh
Priority claimed from CN201010521990.5A external-priority patent/CN101979556B/zh
Priority claimed from CN201010521948.3A external-priority patent/CN101979553B/zh
Priority claimed from CN201010521962.3A external-priority patent/CN101979554B/zh
Priority claimed from CN201010521972.7A external-priority patent/CN102021170B/zh
Priority claimed from PCT/CN2011/071107 external-priority patent/WO2012109798A1/en
Application filed by Benitec Biopharma Limited filed Critical Benitec Biopharma Limited
Publication of LT3124610T publication Critical patent/LT3124610T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of Eletrric Generators (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
LTEP16188642.9T 2010-10-28 2011-10-27 Hbv gydymas LT3124610T (lt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN201010522003.3A CN101979557B (zh) 2010-10-28 2010-10-28 一种siRNA分子及其在抗病毒药物中的应用
CN201010522005.2A CN101979558B (zh) 2010-10-28 2010-10-28 一种靶向乙型肝炎病毒基因的siRNA分子及其应用
CN201010521975.0A CN101979555B (zh) 2010-10-28 2010-10-28 一种小干扰rna分子及其应用
CN201010521990.5A CN101979556B (zh) 2010-10-28 2010-10-28 一种siRNA靶向分子及其应用
CN201010521948.3A CN101979553B (zh) 2010-10-28 2010-10-28 一种干扰HBV基因的siRNA分子及其抗病毒应用
CN201010521962.3A CN101979554B (zh) 2010-10-28 2010-10-28 一种干扰HBV基因的siRNA分子及其应用
CN201010521972.7A CN102021170B (zh) 2010-10-28 2010-10-28 一种干扰乙型肝炎病毒基因的siRNA分子及其应用
PCT/CN2011/071107 WO2012109798A1 (en) 2011-02-18 2011-02-18 Hbv treatment

Publications (1)

Publication Number Publication Date
LT3124610T true LT3124610T (lt) 2019-08-12

Family

ID=45993174

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16188642.9T LT3124610T (lt) 2010-10-28 2011-10-27 Hbv gydymas

Country Status (21)

Country Link
US (2) US9080174B2 (lt)
EP (2) EP2633051B1 (lt)
KR (2) KR101903778B1 (lt)
CN (1) CN103370415B (lt)
AU (1) AU2011320437B2 (lt)
BR (1) BR112013010525A2 (lt)
CA (1) CA2853613C (lt)
CY (1) CY1121894T1 (lt)
DK (1) DK3124610T3 (lt)
ES (1) ES2730393T3 (lt)
HR (1) HRP20190995T1 (lt)
HU (1) HUE044426T2 (lt)
LT (1) LT3124610T (lt)
PL (1) PL3124610T3 (lt)
PT (1) PT3124610T (lt)
RS (1) RS58982B1 (lt)
RU (1) RU2620966C2 (lt)
SI (1) SI3124610T1 (lt)
SM (1) SMT201900317T1 (lt)
TR (1) TR201908127T4 (lt)
WO (1) WO2012055362A1 (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347253B (es) 2011-04-21 2017-04-20 Ionis Pharmaceuticals Inc Modulación de la expresión del virus de hepatitis b (vhb).
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
CN105002214B (zh) * 2015-04-08 2018-07-17 许中伟 用于载体表达的复合多联gRNA和RNAi的表达框架
AU2016257150B2 (en) * 2015-05-06 2022-03-31 Benitec IP Holdings Inc. Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
WO2017027350A2 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
TWI840950B (zh) 2016-03-14 2024-05-01 瑞士商赫孚孟拉羅股份公司 用於降低pd-l1表現之寡核苷酸
WO2017190197A1 (en) * 2016-05-05 2017-11-09 Benitec Biopharma Limited Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
EP3472346B1 (en) 2016-06-17 2023-01-18 F. Hoffmann-La Roche AG Papd5 and papd7 inhibitors for treating a hepatitis b infection
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
CN108929870B (zh) * 2017-05-19 2020-01-24 百奥迈科生物技术有限公司 抑制HBV的siRNA分子及其应用
TW202424191A (zh) 2017-10-16 2024-06-16 瑞士商赫孚孟拉羅股份公司 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
SG11202009680XA (en) 2018-04-05 2020-10-29 Hoffmann La Roche Use of fubp1 inhibitors for treating hepatitis b virus infection
PE20220013A1 (es) 2018-07-03 2022-01-11 Hoffmann La Roche Oligonucleotidos para modular la expresion de tau
BR112021000538A2 (pt) 2018-07-13 2021-04-06 F. Hoffmann-La Roche Ag Oligonucleotídeos para modular a expressão de rtel1
JP7634542B2 (ja) 2019-12-19 2025-02-21 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
CN114829601A (zh) 2019-12-19 2022-07-29 豪夫迈·罗氏有限公司 Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
JP7653997B2 (ja) 2019-12-19 2025-03-31 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
CN114867856A (zh) 2019-12-19 2022-08-05 豪夫迈·罗氏有限公司 Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
JP2023538630A (ja) 2020-08-21 2023-09-08 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
TW202246500A (zh) 2021-02-02 2022-12-01 瑞士商赫孚孟拉羅股份公司 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
WO2023111210A1 (en) 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Combination of oligonucleotides for modulating rtel1 and fubp1
WO2024175111A2 (en) * 2023-02-24 2024-08-29 Suzhou Sanegene Bio Inc. Small interfering rna targeting hbv and uses thereof
CN118995698A (zh) * 2023-05-17 2024-11-22 南京晖丽生物科技有限公司 小核酸在制备治疗猫传染性腹膜炎药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
KR20010042069A (ko) 1998-03-20 2001-05-25 베니텍 오스트레일리아 리미티드 유전자 발현 조절방법
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
EP1424895B1 (en) 2001-09-13 2009-08-12 California Institute Of Technology Method for expression of small antiviral rna molecules within a cell
WO2004020605A2 (en) 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
NZ543815A (en) 2003-06-03 2008-08-29 Benitec Australia Ltd Double-stranded nucleic acid
WO2005087926A2 (en) 2004-03-05 2005-09-22 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of rnai agents
WO2006084209A2 (en) 2005-02-03 2006-08-10 Benitec, Inc. Rnai expression constructs
US8008468B2 (en) * 2005-02-16 2011-08-30 Benitec, Inc. RNAi expression constructs with liver-specific enhancer/promoter
AR057252A1 (es) * 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
WO2007120533A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
CN101684478B (zh) * 2009-06-26 2012-02-29 武汉大学 一种串联表达小干扰rna重组慢病毒载体的构建方法
CN101979556B (zh) * 2010-10-28 2015-01-21 百奥迈科生物技术有限公司 一种siRNA靶向分子及其应用

Also Published As

Publication number Publication date
KR101903778B1 (ko) 2018-10-04
CN103370415A (zh) 2013-10-23
RU2013124422A (ru) 2014-12-10
PT3124610T (pt) 2019-06-14
RS58982B1 (sr) 2019-08-30
CY1121894T1 (el) 2020-10-14
TR201908127T4 (tr) 2019-06-21
US9080174B2 (en) 2015-07-14
WO2012055362A1 (en) 2012-05-03
KR20140071949A (ko) 2014-06-12
ES2730393T3 (es) 2019-11-11
EP2633051A4 (en) 2014-04-23
BR112013010525A2 (pt) 2016-08-02
EP2633051A1 (en) 2013-09-04
SI3124610T1 (sl) 2019-08-30
HRP20190995T1 (hr) 2019-08-09
SMT201900317T1 (it) 2019-09-09
CA2853613A1 (en) 2012-05-03
US9410154B2 (en) 2016-08-09
CN103370415B (zh) 2017-05-31
AU2011320437A1 (en) 2013-06-13
AU2011320437B2 (en) 2017-03-16
RU2620966C2 (ru) 2017-05-30
EP3124610A1 (en) 2017-02-01
PL3124610T3 (pl) 2019-09-30
HUE044426T2 (hu) 2019-10-28
EP3124610B1 (en) 2019-03-06
US20130296401A1 (en) 2013-11-07
US20150344885A1 (en) 2015-12-03
EP2633051B1 (en) 2016-09-14
DK3124610T3 (da) 2019-06-11
KR20180110186A (ko) 2018-10-08
CA2853613C (en) 2020-03-24

Similar Documents

Publication Publication Date Title
HUE044426T2 (hu) HBV kezelés
PL2652193T3 (pl) Obróbka
GB2478797B (en) Waste treatment
PH12013500022A1 (en) Surface treatment
EP2521569A4 (en) COMBINATION THERAPY WITH VB-201
EP2521550A4 (en) METHOD OF TREATMENT
GB0900599D0 (en) Treatment
GB201013573D0 (en) Treatment
EP2560679A4 (en) TREATMENT OF ECZEMA
GB0913968D0 (en) Treatment
ZA201308117B (en) Avian-based treatment
GB201001521D0 (en) Treatment
GB201014097D0 (en) Treatment
GB201102283D0 (en) Treatment
GB201021319D0 (en) Treatment
GB2483219B (en) Surface Treatment
GB201014736D0 (en) Treatment of hepatitis C
GB201102267D0 (en) Treatment
GB201111247D0 (en) Treatment
GB201102274D0 (en) Treatment
GB201102275D0 (en) Treatment
GB201102276D0 (en) Treatment
GB201102277D0 (en) Treatment
GB201102282D0 (en) Treatment
GB201102272D0 (en) Treatment